Launch of the Late-Stage Phase II Clinical Trial for KRP-N118
First written in FY2019-Q2. 1 of 3 entries say "Cited as achieved", first in FY2019. Latest entry: FY2020-Q3.
No other company in this theme has enough history to compare yet.
- FY2020-Q3DroppedAnnual report
「The company entered into a license agreement for KRP-N118/SK-1404, a treatment for nocturia caused by nocturnal polyuria, and had been developing the compound, which was at the late-stage Phase II clinical trial stage. However, the company determined that it would be difficult to achieve the product profile initially established and discontinued development of the compound, as well as」
Development of KRP-N118, which had progressed through late-stage Phase II clinical trials, was discontinued because the company determined that it would be difficult to achieve the product profile. - FY2019Cited as achievedAnnual report
「In August of the same year, we began a late-stage Phase II clinical trial of KRP-N118, a treatment for nocturia associated with nocturnal polyuria.」
The company cites the start of the late-stage Phase II clinical trial of KRP-N118 as an achievement for the fiscal year. - FY2019-Q2First statedAnnual report
「We began a late-stage Phase II clinical trial in August for KRP-N118, a treatment for nocturia associated with nocturnal polyuria.」
A late-stage Phase II clinical trial for KRP-N118 began in August 2018.